Form 4: Ironwood CFO Sells Shares for Tax Obligations

Ironwood Pharmaceuticals' CFO, Gregory S. Martini, sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Gregory S. Martini, Chief Financial Officer of Ironwood Pharmaceuticals Inc. (IRWD), reported sales of Class A Common Stock.
• On February 23, 2026, 10,487 shares were sold at a weighted average price of $3.81 per share, with prices ranging from $3.70 to $4.05.
• On February 24, 2026, an additional 11,457 shares were sold at a weighted average price of $3.66 per share, with prices ranging from $3.60 to $3.73.
• These sales were non-discretionary, executed automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• Following these transactions, Gregory S. Martini beneficially owns 160,601 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. The sales are non-discretionary and solely for tax purposes, thus not reflecting a change in the insider's confidence or a negative outlook on the company's fundamentals.

Positives

• The underlying event, the vesting of restricted stock units, represents a form of compensation for the executive, indicating continued alignment with company performance.

Negatives

• The reported sales are non-discretionary 'sell to cover' transactions for tax withholding, and therefore do not signal a lack of confidence in the company by the insider.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The sale reported on this Form 4 represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine occurrence for executives receiving equity compensation, particularly in the pharmaceutical and biotechnology sectors where stock-based compensation is prevalent. These sales are typically not indicative of an executive's sentiment towards the company's future prospects, unlike discretionary open-market sales.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales for tax purposes and do not signal a change in company fundamentals or insider sentiment.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, Form 4, Insider Trading, Stock Sale, CFO, Restricted Stock Units, Tax Withholding